futibatinib
Selected indexed studies
- Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. (N Engl J Med, 2023) [PMID:36652354]
- Futibatinib. (, 2006) [PMID:37247363]
- Futibatinib: First Approval. (Drugs, 2022) [PMID:36441501]
_Worker-drafted node — pending editorial review._
Connections
futibatinib is a side effect of
Sources
- Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. (2023) pubmed
- Futibatinib. (2006) pubmed
- Futibatinib: First Approval. (2022) pubmed
- Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study. (2022) pubmed
- Futibatinib. (2012) pubmed
- Futibatinib: A Review in Locally Advanced and Metastatic Cholangiocarcinoma. (2024) pubmed
- Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors. (2023) pubmed
- PMID:39812563 (2024) pubmed
- Futibatinib. (2023) pubmed
- Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma. (2023) pubmed